Biosynthetic Human Proinsulin: Review of Chemistry, in Vitro and in Vivo Receptor Binding, Animal and Human Pharmacology Studies, and Clinical Trial Experience

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Diabetes Care

• Publication date

  1992-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2337/diacare.15.5.666PMID 1516487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Proinsulin conversion intermediates: a possible source of confusion

  1991cited by this paper
• The interaction of proinsulin with the insulin-like growth factor-I receptor in human liver, muscle, and adipose tissue.

  1991cited by this paper
• The effects of human proinsulin on glucose turnover and intermediary metabolism.

  1991cited by this paper
• Rotation of the anatomic regions used for insulin injections and day-to-day variability of plasma glucose in type I diabetic subjects.

  1991cited by this paper
• A Randomized Cross‐over Study of the Effects of Proinsulin on Lipid Metabolism in Type 2 Diabetes

  1991cited by this paper
• Insulin agonist therapy: a challenge for the 1990s.

  1990cited by this paper
• Comparisons of Insulin and Biosynthetic Human Proinsulin Actions in Cultured Hepatocytes

  1990cited by this paper
• Monomeric Insulins and Their Experimental and Clinical Implications

  1990cited by this paper
• Hypoglycemic potency and metabolic clearance rate of intravenously administered human proinsulin and metabolites.

  1990cited by this paper
• The relationships of concentrations of insulin, intact proinsulin and 32–33 split proinsulin with cardiovascular risk factors in Type 2 (non-insulin-dependent) diabetic subjects

  1990cited by this paper
• Insulin and atheroma. 20-yr perspective.

  1990cited by this paper
• Treatment of NIDDM With Insulin Agonists or Substitutes

  1990cited by this paper
• Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins.

  1989cited by this paper
• Hypoglycemia in insulin-dependent diabetes mellitus.

  1989cited by this paper
• Elevated Proinsulin in Healthy Siblings of IDDM Patients Independent of HLA Identity

  1989cited by this paper
• Metabolic effects of biosynthetic human proinsulin in type 2 diabetes mellitus

  1989cited by this paper
• Insulin deficiency in non-insulin-dependent diabetes.

  1989cited by this paper
• Circulating insulin-like growth factor I in Type 1 (insulin-dependent) diabetic patients with retinopathy

  1989cited by this paper
• Human proinsulin. Does it improve the treatment of type I diabetics?

  1988cited by this paper
• Bioactivity and Pharmakokinetics of Human Proinsulin in Comparison to Human Insulin after Intravenous and Subcutaneous Injection

  1988cited by this paper
• Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes

  1988cited by this paper
• Atherosclerosis in diabetes: the role of hyperinsulinemia.

  1988cited by this paper
• Action profile of biosynthetic human proinsulin trials with the BIOSTATOR in metabolically normal subjects.

  1988cited by this paper
• New drug development in the United States, 1963 through 1984

  1988cited by this paper
• Scintigraphic distribution of 123 I labelled proinsulin, split conversion intermediates and insulin in rats

  1988cited by this paper
• Metabolic effects of intravenous proinsulin.

  1988cited by this paper
• Effects of single and combined infusions of human biosynthetic proinsulin and insulin on glucose metabolism and on plasma hormone concentrations in euglycaemic clamp experiments.

  1988cited by this paper
• Comparative study of hormonal counterregulation during GCIIS-guided hypoglycemia tests using human proinsulin and human insulin (recombinant DNA).

  1988cited by this paper
• Binding of proinsulin and proinsulin conversion intermediates to human placental insulin-like growth factor I receptors.

  1988cited by this paper
• Is insulin atherogenic?

  1988cited by this paper
• Qualitative dissimilarities of insulin and proinsulin binding and action in vitro at IM 9-lymphocytes.

  1988cited by this paper
• Biosynthetic human proinsulin, a new therapeutic compound for diabetics? A comparative study of biosynthetic human proinsulin with biosynthetic human insulin.

  1988cited by this paper
• Pharmacokinetics of biosynthetic human proinsulin following intravenous and subcutaneous administration in metabolically healthy volunteers.

  1988cited by this paper
• The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM

  1988cited by this paper
• Substitution of basal delivery of insulin by proinsulin in type I diabetic patients under CSII.

  1988cited by this paper
• Conversion of biosynthetic human proinsulin to partially cleaved intermediates by collagenase proteinases adsorbed to isolated rat adipocytes.

  1988cited by this paper
• Effects of biosynthetic human proinsulin on plasma lipids in type 2 diabetes mellitus

  1988cited by this paper
• Human Proinsulin Normalizes Fasting Hyperglycemia in Patients With NIDDM

  1988cited by this paper
• Endocytotic uptake, processing, and retroendocytosis of human biosynthetic proinsulin by rat fibroblasts transfected with the human insulin receptor gene.

  1988cited by this paper
• Clinical investigations into the modification of the effect of endogenous and exogenous insulin by human proinsulin in type II and type I diabetics.

  1988cited by this paper
• Kinetics of biosynthetic human proinsulin in patients with terminal renal insufficiency.

  1988cited by this paper
• The effect of biosynthetic human proinsulin on the hepatic response to glucagon in insulin-deficient diabetes.

  1987cited by this paper
• Disproportionate elevation of immunoreactive proinsulin in Type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance

  1987cited by this paper
• Diabetes and atherosclerosis: an epidemiologic view.

  1987cited by this paper
• The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus.

  1987cited by this paper
• The effect of biosynthetic human proinsulin on intermediary metabolism

  1987cited by this paper
• Selective suppression of hepatic glucose output by human proinsulin in the dog.

  1987cited by this paper
• Characterization and Use in Immunoradiometric Assay of Monoclonal Antibodies Directed Against Human Proinsulin

  1987cited by this paper
• Differential Effects of Insulin- and Proinsulin-Induced Hypoglycemia on Pituitary Hormone and Catecholamine Secretion

  1987cited by this paper
• Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia.

  1986cited by this paper
• In Vivo Deactivation of Proinsulin Action on Glucose Disposal and Hepatic Glucose Production in Normal Man

  1986cited by this paper
• The effects of proinsulin pretreatment on the combined actions of insulin and proinsulin in normal man.

  1986cited by this paper
• Regulation of Ketogenesis, Gluconeogenesis, and Glycogen Synthesis by Insulin and Proinsulin in Rat Hepatocyte Monolayer Cultures

  1986cited by this paper
• Inhibition by proinsulin of endogenous C-peptide release in healthy man.

  1986cited by this paper
• Receptor binding and biological potency of several split forms (conversion intermediates) of human proinsulin. Studies in cultured IM-9 lymphocytes and in vivo and in vitro in rats.

  1985cited by this paper
• Measurement of Circulating Human Proinsulin Concentrations Using a Proinsulin-specific Antiserum

  1985cited by this paper
• Biochemical and clinical implications of proinsulin conversion intermediates.

  1985cited by this paper
• Biological potency of porcine, bovine and human insulins in the rabbit bioassay system

  1985cited by this paper
• A Radioimmunoassay for Circulating Human Proinsulin

  1985cited by this paper
• Insulin-like Action of Proinsulin on Rat Liver Carbohydrate Metabolism In Vitro

  1985cited by this paper
• In Vitro Activity of Biosynthetic Human Proinsulin: Receptor Binding and Biologic Potency of Proinsulin and Insulin in Isolated Rat Adipocytes

  1984cited by this paper
• The metabolic effects of biosynthetic human proinsulin in individuals with type I diabetes.

  1984cited by this paper
• Biologic and clinical importance of proinsulin.

  1984cited by this paper
• In Vitro Characterization of Biosynthetic Human Proinsulin

  1984cited by this paper
• The Effects of Biosynthetic Human Proinsulin on Carbohydrate Metabolism

  1984cited by this paper
• Insulin-like growth factors. Studies in diabetics with and without retinopathy.

  1983cited by this paper
• New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus.

  1983cited by this paper
• UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year.

  1983cited by this paper
• Evidence for an association between rheumatoid arthritis and autoimmune endocrine disease.

  1983cited by this paper
• Authenticity and Purity of Human Insulin (recombinant DNA)

  1982cited by this paper
• Less Pronounced Changes in Serum Potassium and Epinephrine During Hypoglycemia Induced by Human Insulin (recombinant DNA)

  1982cited by this paper
• Receptor Binding Properties of Human Insulin (recombinant DNA) and Human Proinsulin and Their Interaction at the Receptor Site

  1982cited by this paper
• Free and total insulin integrated concentrations in insulin dependent diabetes.

  1982cited by this paper
• Comparative Studies on Intermediary Metabolism and Hormonal Counterregulation Following Human Insulin (recombinant DNA) and Purified Pork Insulin in Man

  1982cited by this paper
• Different Counterregulatory Responses to Human Insulin (recombinant DNA) and Purified Pork Insulin

  1982cited by this paper
• Chemical, Physical, and Biologic Properties of Biosynthetic Human Insulin

  1981cited by this paper
• Mechanism of action of insulin and insulin analogues

  1981cited by this paper
• Effects of Liver and Kidney on High Molecular Weight Immunoreactive Insulin (HWIRI), Proinsulin (PI) and Insulin (I) in Man

  1981cited by this paper
• Non-parallel evolution of metabolic and growth-promoting functions of insulin

  1981cited by this paper
• Inhibition of access of bound somatomedin to membrane receptor and immunobinding sites: a comparison of radioreceptor and radioimmunoassay of somatomedin in native and acid-ethanol-extracted serum.

  1980cited by this paper
• Diabetes and atherosclerosis — The role of insulin

  1979cited by this paper
• The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin.

  1978cited by this paper
• Primary structure of human insulin‐like growth factor II

  1978cited by this paper
• Hyperlipidemia and atherosclerosis.

  1976cited by this paper
• Biological properties of chemically modified insulins. I. Biological activity of proinsulin and insulin modified at A1-glycine and B29-lysine

  1976cited by this paper
• Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.

  1975cited by this paper
• A comparative study on the metabolism of human insulin and porcine proinsulin in man.

  1973cited by this paper
• [Proinsulin and biosynthesis of insulin].

  1973cited by this paper
• Effects of Comparative Perfusions of Equimolar, Single Component Insulin and Proinsulin in the Human Forearm

  1973cited by this paper
• Metabolism of proinsulin, insulin, and C-peptide in the rat.

  1973cited by this paper
• Clinical Aspects of Insulin–Antigenicity

  1972cited by this paper
• Immunogenicity of Insulin

  1972cited by this paper
• Amino Acid Sequences of Proinsulins and Intermediates

  1972cited by this paper
• Hypoglycemic activity and immunological half-life of porcine insulin and proinsulin in baboons and swine.

  1971cited by this paper
• The effects of low doses of intravenous proinsulin and insulin combinations in normal fasted man.

  1971cited by this paper
• Proinsulin. The single chain precursor of insulin.

  1970cited by this paper
• Porcine Proinsulin: Characterization and Amino Acid Sequence

  1968cited by this paper
• Isolation and Properties of Proinsulin, Intermediate Forms, and Other Minor Components from Crystalline Bovine Insulin

  1968cited by this paper
• The biosynthesis of insulin and a probable precursor of insulin by a human islet cell adenoma.

  1967cited by this paper

• In Silico Hypothesis Testing in Drug Discovery: Using Quantitative Systems Pharmacology Modeling to Evaluate the Therapeutic Value of Proinsulin Conversion to Insulin Therapy for Type 2 Diabetes Mellitus

  2025cites this paper
• Evaluation of proinsulin(F25D) as a targeting ligand for insulin-binding B cells in autoimmune diabetes

  2025influential citation
• Engineered Nonhormonal, Cationic Proinsulin Variants Prolong Lymphatic Drainage.

  2025cites this paper
• Understanding Insulin in the Age of Precision Medicine and Big Data: Under-Explored Nature of Genomics

  2023cites this paper
• Recent advancements on novel approaches of insulin delivery

  2023cites this paper
• Structural Lessons From the Mutant Proinsulin Syndrome

  2021cites this paper
• Proinsulin to C-peptide Ratio in the First Year Post Diagnosis of Type 1 Diabetes.

  2021cites this paper
• Diabetes Mellitus due to Toxic Misfolding of Proinsulin Variants.

  2021cites this paper
• Altered islet prohormone processing: A cause or consequence of diabetes?

  2021cites this paper
• The Evolution of Insulin and How it Informs Therapy and Treatment Choices

  2020influential citation
• A Review on Insulin Formulations for Diabetes Mellitus Therapy

  2020cites this paper
• The ketogenic diet corrects metabolic hypogonadism and preserves pancreatic ß-cell function in overweight/obese men: a single-arm uncontrolled study

  2020cites this paper
• Recent advances in the chemical synthesis of insulin and related peptides.

  2020cites this paper
• Removing, replacing, and processing proinsulin in beta-cells

  2019cites this paper
• Insulin and its single-chain analogue

  2019cites this paper
• The Prohormone Proinsulin as a Neuroprotective Factor: Past History and Future Prospects

  2018cites this paper
• John A. Galloway, MD, FACP: A Pharmaceutical Physician and Leader in Diabetes Therapy

  2018cites this paper
• Insulin Receptor Isoforms in Physiology and Disease: An Updated View

  2017cites this paper
• Clinical and Laboratory Evaluation of a New Specific Point-of-Care Test for Intact Proinsulin

  2017cites this paper
• Hyperproinsulinemia in obesity and in type 2 diabetes and its relation to cardiovascular disease

  2017cites this paper
• An ultra-stable single-chain insulin analog resists thermal inactivation and exhibits biological signaling duration equivalent to the native protein

  2017cites this paper
• Mesenchymal Stem Cell Differentiation into Adipocytes Is Equally Induced by Insulin and Proinsulin In Vitro

  2017cites this paper
• Production of Recombinant Pharmaceutical Proteins

  2016cites this paper
• Biosynthesis, Processing, and Secretion of the Islet Hormones

  2016cites this paper
• Metabolic Risk Factors for Heart Failure

  2016cites this paper
• Administration of olanzapine as an antiemetic agent changes glucose homeostasis in cisplatin-treated rats.

  2015cites this paper
• Insulin, The Renin-Angiotensin-Aldosterone System and Blood Pressure

  2015cites this paper
• Combination Therapy «Metformin + Glimepiride» in Patients with Type 2 Diabetes Mellitus (Molecular Mechanisms for Optimization of the Rehabilitation Effect)

  2015cites this paper
• Pathophysiology of Type 2 diabetes mellitus & vascular disease

  2015cites this paper
• Elevated Intact Proinsulin Levels During an Oral Glucose Challenge Indicate Progressive ß-Cell Dysfunction and May Be Predictive for Development of Type 2 Diabetes

  2015cites this paper
• Proinsulin and IGFBP-1 predicts mortality in an elderly population.

  2014cites this paper
• On anti-diabetic agents and the vasculature

  2014cites this paper
• Stoornissen van het glucosemetabolisme – forensische postmortemanalyses: deel I

  2014cites this paper
• Role of Injured Pancreatic Extract Promotes Bone Marrow-Derived Mesenchymal Stem Cells Efficiently Differentiate into Insulin-Producing Cells

  2013cites this paper
• Diabetes mellitus due to the toxic misfolding of proinsulin variants

  2013cites this paper
• Pancreatic β-Cell Dysfunction and Risk of New-Onset Diabetes After Kidney Transplantation

  2013cites this paper
• Discovery of high potency, single-chain insulin analogs with a shortened B-chain and nonpeptide linker.

  2013cites this paper
• Pancreatic b-Cell Dysfunction and Risk of New-Onset Diabetes After Kidney Transplantation

  2013cites this paper
• Effects of Long-Acting Insulin Analogues on Breast and Colon Cancer Promotion

  2013cites this paper
• Metabolic Syndrome and associated pathologies

  2013cites this paper
• Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control

  2012cites this paper
• Proinsulin Slows Retinal Degeneration and Vision Loss in the P23H Rat Model of Retinitis Pigmentosa

  2012influential citation
• Proinsulin binds with high affinity the insulin receptor isoform A and predominantly activates the mitogenic pathway.

  2012cites this paper
• The insulin receptor isoform A: a mitogenic proinsulin receptor?

  2012cites this paper
• In Type 2 Diabetes Patients, Insulin Glargine is Associated with Lower Postprandial Release of Intact Proinsulin Compared with Sulfonylurea Treatment

  2012cites this paper
• Adaptation of the endogenous insulin secretion in non-insulin-dependent diabetes by an individual sport therapeutic intervention - a pilot study.

  2012cites this paper
• Disorders of glucose metabolism: post mortem analyses in forensic cases–part II

  2011cites this paper
• Insulin Preparations with Prolonged Effect

  2011cites this paper
• Admission proinsulin is associated with mortality in patients with admission hyperglycemia during acute coronary syndrome: results from a pilot observational study.

  2011cites this paper
• Elevated Intact Proinsulin Levels are Indicative of Beta-Cell Dysfunction, Insulin Resistance, and Cardiovascular Risk: Impact of the Antidiabetic Agent Pioglitazone

  2011cites this paper
• ASSOCIATIONOF PROINSULIN WITH CARDIOVASCULAR RISK IN NONDIABETIC SUBJECTS

  2011cites this paper
• Review of approved pioglitazone combinations for type 2 diabetes

  2011cites this paper
• Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells.

  2011cites this paper
• Non-glycemic effects of insulin therapy: a comparison between insulin aspart and regular human insulin during two consecutive meals in patients with type 2 diabetes.

  2011cites this paper
• Disorders of glucose metabolism–post mortem analyses in forensic cases: part I

  2011cites this paper
• In Adult

  2010cites this paper
• Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial β-cell protection in individuals with type 2 diabetes

  2010cites this paper
• The Impact of Bariatric Surgery on Obesity related Metabolic Traits with Specific Emphasis on Glucose, Insulin and Proinsulin

  2010cites this paper
• Deciphering the Hidden Informational Content of Protein Sequences

  2010cites this paper
• The insulin secretory granule as a signaling hub.

  2010cites this paper
• Limitations of the HOMA-B Score for Assessment of β-Cell Functionality in Interventional Trials—Results from the PIOglim study

  2010cites this paper
• Skeletal muscle metabolism in the pathology and treatment of type 1 diabetes.

  2010cites this paper
• New developments in the treatment of type 1 diabetes mellitus.

  2009cites this paper
• Cardiovascular Effects of Disturbed Insulin Activity in Metabolic Syndrome and in Type 2 Diabetic Patients

  2009cites this paper
• Proinsulin and the Genetics of Diabetes Mellitus*

  2009cites this paper
• Crystal Structure of a “Nonfoldable” Insulin

  2009cites this paper
• A brief perspective on insulin production

  2009cites this paper
• Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients.

  2009cites this paper
• Proinsulin in pregnant women with normal glucose tolerance or mild gestational diabetes mellitus.

  2009cites this paper
• A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus.

  2008cites this paper
• Insulin sensitivity measured by the euglycaemic insulin clamp and proinsulin levels as predictors of stroke in elderly men

  2008cites this paper
• PROINSULIN, PROAMYLIN AND THE BETA CELL ENDOPLASMIC RETICULUM: THE KEY FOR THE PATHOGENESIS OF DIFFERENT DIABETES PHENOTYPES

  2007cites this paper
• Proinsulin:insulin and insulin:glucose ratios as predictors of carotid plaque growth: a population-based 7 year follow-up of the Tromsø Study

  2007cites this paper
• The Center for Food Safety (CFS) submits the following comments on the United States Department of Agriculture (USDA) Animal and Plant Health Inspection Service (APHIS)’s environmental assessment and preliminary decision to allow SemBioSys Genetics, Inc., to plant genetically engineered proinsulin-p

  2007cites this paper
• Insulin structure and function.

  2007cites this paper
• Proinsulin Is an Independent Predictor of the Angiographical Characteristics of Coronary Atherosclerosis

  2007cites this paper
• Nice insulins, pity about the evidence

  2007cites this paper
• Gastric bypass alters the dynamics and metabolic effects of insulin and proinsulin secretion

  2007cites this paper
• A Diabetes Outcome and Progression Trial – Die ADOPT Studie

  2007cites this paper
• High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus

  2006cites this paper
• Fibrinolytic dysfunction in insulin‐resistant women with previous gestational diabetes

  2006cites this paper
• Association of serum proinsulin with hormone replacement therapy in nondiabetic older women: the Rancho Bernardo Study.

  2006cites this paper
• Diabetes Mellitus : Implications for Physical Therapy Pharmacologic Management of Hyperglycemia in

  2006cites this paper
• The Switch from Sulfonylurea to Preprandial Short- Acting Insulin Analog Substitution Has an Immediate and Comprehensive β-Cell Protective Effect in Patients with Type 2 Diabetes Mellitus

  2006cites this paper
• Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin.

  2005cites this paper
• Insulin sensitivity, proinsulin and insulin as predictors of coronary heart disease. A population-based 10-year, follow-up study in 70-year old men using the euglycaemic insulin clamp

  2005cites this paper
• Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: an 11-year follow-up of the Hoorn Study.

  2005cites this paper
• Novel metabolic risk factors for heart failure.

  2005cites this paper
• A Potential Risk Factor for Vascular Disease

  2005cites this paper
• IRIS II Study: Intact Proinsulin Is Confirmed as a Highly Specific Indicator for Insulin Resistance in a Large Cross-Sectional Study Design

  2005cites this paper
• Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes.

  2004cites this paper
• IRIS II Study: Sensitivity and Specificity of Intact Proinsulin, Adiponectin, and the Proinsulin/Adiponectin Ratio as Markers for Insulin Resistance

  2004cites this paper
• Role of Intact Proinsulin in Diagnosis and Treatment of Type 2 Diabetes Mellitus

  2004cites this paper
• Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1354 Clinical Manifestations of Coronary Heart Disease and the Metabolic Syndrome A Population-based Study in Middle-aged Men in Uppsala

  2004cites this paper
• Cardiovascular risk factors for stable angina pectoris versus unheralded myocardial infarction.

  2004cites this paper
• Gene therapy of streptozotocin‐induced diabetes by intramuscular delivery of modified preproinsulin genes

  2003cites this paper
• A clinical pharmacologist's view of drug toxicity.

  2003cites this paper
• Association of hyperglycemia and insulin with diabetic cardiovascular complications.

  2003cites this paper
• The diagnosis of fasting hypoglycemia due to an islet-cell tumor obscured by a highly specific insulin assay.

  2003cites this paper
• Basal and dynamic proinsulin-insulin relationship to assess beta-cell function during OGTT in metabolic disorders.

  2003cites this paper